Cargando…
E‐cigarette or vaping product use‐associated lung injury (EVALI) features and recognition in the emergency department
Since August 2019, the pulmonary disease termed e‐cigarette or vaping product‐use associated lung injury (EVALI), has resulted in 2758 hospitalizations and 64 deaths in the United States. EVALI is considered in patients who have vaped or dabbed within 90 days of symptom onset, and have abnormal lung...
Autores principales: | Aldy, Kim, Cao, Dazhe James, Weaver, Mary Madison, Rao, Devika, Feng, Sing‐Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593457/ https://www.ncbi.nlm.nih.gov/pubmed/33145562 http://dx.doi.org/10.1002/emp2.12112 |
Ejemplares similares
-
E‐cigarette or vaping product use‐associated lung injury (EVALI) characterized by pulmonary ultrasound
por: Sacci, Peter, et al.
Publicado: (2020) -
E-CIGARETTE OR VAPING USE-ASSOCIATED LUNG INJURY (EVALI): EFFECTS OF VAPING OR COVID-19?
por: WALBRIDGE, GEORGE, et al.
Publicado: (2022) -
Suggested management of e-cigarette or vaping product use associated lung injury (EVALI)
por: Hage, René, et al.
Publicado: (2020) -
E-cigarette or Vaping Product Associated Lung Injury (EVALI) Presenting As Cardiac Arrest
por: Schekochikhina, Natalia, et al.
Publicado: (2022) -
Chemical Constituents Involved in E-Cigarette, or Vaping Product Use-Associated Lung Injury (EVALI)
por: Muthumalage, Thivanka, et al.
Publicado: (2020)